ALPS is our proprietary artificial intelligence-based R&D platform to identify optimal molecular targets for cancer therapy. ALPS leverages advanced gene editing, sequencing, and single cell technologies to deliver thousands upon thousands of data points related to the biology of antitumor immunity. These data points are fed into sophisticated algorithms that model complex phenotypes of T cells in the tumor microenvironment. These models help us predict potential responses to new treatments and define biomarker signatures, which we expect to lead to safer and more informative clinical trials. Ultimately, the data we collect from clinical trials will be fed back into our algorithms, strengthening our predictive models and optimizing patient outcomes over time.